Reports
Sale
Asia Pacific Biobanking Market Size, Share, Trends, Analysis: By Product and Service: Equipment, Consumables, Service, Software; By Application: Regenerative Medicine, Life Science Research, Clinical Research; By Sample Type: Blood Tissue, Nucleic Acids Cell Lines; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific Biobanking Market Outlook
The global biobanking market size was valued at USD 72.1 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the increased investments from both government and private sectors in biobanking. It is expected to grow at a CAGR of 6.89% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.
Key Takeaways
- Asia Pacific is reported to have a high prevalence of chronic diseases, with the data revealing that 1 in every 4 people in India has a risk of dying from a noncommunicable disease. This rising burden of chronic disease is expected to stimulate the development of novel drugs, thereby impacting the market demand.
- In July 2023, CU Medicine successfully established the CU-Med Biobank , an internationally accredited biobank in Hong Kong, which is expected to turn it into an important biomedical research hub. The increased investment in the establishment of biobanks is likely to augment the Asia Pacific biobanking market share.
- The increased recognition of biobanks as a valuable resource for researchers to study the disease onset and progression is elevating the market value. In November 2023, an INR 20 crore biobank was launched in South India, the third such facility in India, to serve as a repository for collaborative research initiatives to map the prevention and reversal of diseases, among others.
Asia Pacific Biobanking Market Analysis
The practice of collecting, preserving, and managing biological samples such as blood, DNA, and tissues, among others, is defined as biobanking. The primary purpose of biobanks is to provide a reliable resource for medical research and development. These specialized facilities act as a repository for biological samples often needed for genetic analysis and biomarker discovery, thus supporting the advancement of personalized treatment therapies. The growing emphasis on genetic research and personalized medicine is significantly contributing to the Asia Pacific biobanking market growth.
The rising burden of chronic diseases has a profound influence on market dynamics. Asia Pacific is reported to have a high prevalence of these chronic conditions, with data revealing that 1 in every 4 people in India are at a risk of dying from a noncommunicable disease such as cancer, diabetes, and cardiovascular disease . Since biobanks are a prerequisite for developing new drugs and advanced diagnostic technologies. Consequently, the demand for these repositories is expected to grow with the rise in chronic disease cases.
One of the major Asia Pacific biobanking market trends is the increased investment in infrastructure development and establishment of biobanks. In July 2023, CU Medicine (Faculty of Medicine, The Chinese University of Hong Kong) successfully established the CU-Med Biobank , an internationally accredited biobank, expected to turn Hong Kong into an important biomedical research hub. The biobank is increasingly used for large-scale genomic research and is likely to attract collaborations from leading pharmaceutical companies and research institutes, thereby elevating the market value in the region.
The growing recognition of biobanks as a valuable resource for researchers to study the onset and progression of diseases is boosting the Asia Pacific biobanking market demand. In November 2023, an INR 20 crore state-of-the-art biobank was launched in South India, the third such facility in the region to serve as a repository for collaborative research initiatives to map the prevention and reversal of diseases, among others. The biobank boasts 23 freezers with a capacity to store over 3 lakh samples. Such advanced biobanks are poised to accelerate innovation in the healthcare sector, ultimately propelling market growth in the coming years.
Asia Pacific Biobanking Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product and Service | Equipment, Consumables, Service, Software |
| Application | Regenerative Medicine, Life Science Research, Clinical Research |
| Sample Type | Blood Tissue, Nucleic Acids, Cell Lines |
| End User | Academic Institutions, Pharma and Biotech Companies |
| Country | China, Japan, India, ASEAN, Australia, Others |
Asia Pacific Biobanking Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- PHC Holdings Corporation
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- QIAGEN N.V.
- Merck KGaA
- Avantor, Inc.
- Cryoport, Inc.
- Tecan Trading AG
- Lifecode Technologies Pte Ltd
- China Cord Blood Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product and Service |
|
| Breakup by Application |
|
| Breakup by Sample Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Biobanking Market Overview
3.1 Asia Pacific Biobanking Market Historical Value (2017-2023)
3.2 Asia Pacific Biobanking Market Forecast Value (2024-2032)
4 Asia Pacific Biobanking Market Landscape*
4.1 Asia Pacific Biobanking: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Biobanking: Product Landscape
4.2.1 Analysis by Product and Service
4.2.2 Analysis by Application
5 Asia Pacific Biobanking Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Biobanking Market Segmentation (2017-2032)
6.1 Asia Pacific Biobanking Market (2017-2032) by Product and Service
6.1.1 Market Overview
6.1.2 Equipment
6.1.3 Consumables
6.1.4 Service
6.1.5 Software
6.2 Asia Pacific Biobanking Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Regenerative Medicine
6.2.3 Life Science Research
6.2.4 Clinical Research
6.3 Asia Pacific Biobanking Market (2017-2032) by Sample Type
6.3.1 Market Overview
6.3.2 Blood Tissue
6.3.3 Nucleic Acids
6.3.4 Cell Lines
6.4 Asia Pacific Biobanking Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Academic Institutions
6.4.3 Pharma and Biotech Companies
6.5 Asia Pacific Biobanking Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 China
6.5.3 Japan
6.5.4 India
6.5.5 ASEAN
6.5.6 Australia
6.5.7 Others
7 China Biobanking Market (2017-2032)
7.1 China Biobanking Market (2017-2032) by Product and Service
7.1.1 Market Overview
7.1.2 Equipment
7.1.3 Consumables
7.1.4 Service
7.1.5 Software
7.2 China Biobanking Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Regenerative Medicine
7.2.3 Life Science Research
7.2.4 Clinical Research
7.3 China Biobanking Market (2017-2032) by Sample Type
7.3.1 Market Overview
7.3.2 Blood Tissue
7.3.3 Nucleic Acids
7.3.4 Cell Lines
7.4 China Biobanking Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Academic Institutions
7.4.3 Pharma and Biotech Companies
8 Japan Biobanking Market (2017-2032)
8.1 Japan Biobanking Market (2017-2032) by Product and Service
8.1.1 Market Overview
8.1.2 Equipment
8.1.3 Consumables
8.1.4 Service
8.1.5 Software
8.2 Japan Biobanking Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Regenerative Medicine
8.2.3 Life Science Research
8.2.4 Clinical Research
8.3 Japan Biobanking Market (2017-2032) by Sample Type
8.3.1 Market Overview
8.3.2 Blood Tissue
8.3.3 Nucleic Acids
8.3.4 Cell Lines
8.4 Japan Biobanking Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Academic Institutions
8.4.3 Pharma and Biotech Companies
9 India Biobanking Market (2017-2032)
9.1 India Biobanking Market (2017-2032) by Product and Service
9.1.1 Market Overview
9.1.2 Equipment
9.1.3 Consumables
9.1.4 Service
9.1.5 Software
9.2 India Biobanking Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Regenerative Medicine
9.2.3 Life Science Research
9.2.4 Clinical Research
9.3 India Biobanking Market (2017-2032) by Sample Type
9.3.1 Market Overview
9.3.2 Blood Tissue
9.3.3 Nucleic Acids
9.3.4 Cell Lines
9.4 India Biobanking Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Academic Institutions
9.4.3 Pharma and Biotech Companies
10 ASEAN Biobanking Market (2017-2032)
10.1 ASEAN Biobanking Market (2017-2032) by Product and Service
10.1.1 Market Overview
10.1.2 Equipment
10.1.3 Consumables
10.1.4 Service
10.1.5 Software
10.2 ASEAN Biobanking Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Regenerative Medicine
10.2.3 Life Science Research
10.2.4 Clinical Research
10.3 ASEAN Biobanking Market (2017-2032) by Sample Type
10.3.1 Market Overview
10.3.2 Blood Tissue
10.3.3 Nucleic Acids
10.3.4 Cell Lines
10.4 ASEAN Biobanking Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Academic Institutions
10.4.3 Pharma and Biotech Companies
11 Australia Biobanking Market (2017-2032)
11.1 Australia Biobanking Market (2017-2032) by Product and Service
11.1.1 Market Overview
11.1.2 Equipment
11.1.3 Consumables
11.1.4 Service
11.1.5 Software
11.2 Australia Biobanking Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Regenerative Medicine
11.2.3 Life Science Research
11.2.4 Clinical Research
11.3 Australia Biobanking Market (2017-2032) by Sample Type
11.3.1 Market Overview
11.3.2 Blood Tissue
11.3.3 Nucleic Acids
11.3.4 Cell Lines
11.4 Australia Biobanking Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Academic Institutions
11.4.3 Pharma and Biotech Companies
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share by Top 5 Companies
17.2 PHC Holdings Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Thermo Fisher Scientific, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Becton, Dickinson and Company
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 QIAGEN N.V.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck KGaA
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Avantor, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Cryoport, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Tecan Trading AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Lifecode Technologies Pte Ltd
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 China Cord Blood Corporation
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Asia Pacific Biobanking Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific biobanking market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032 and is likely to reach a market value of USD 131.1 billion by 2032.
The rising emphasis on the advancement of genetic research and personalized medicine along with increasing medical research expenditure is fuelling the demand for the market.
One of the significant trends in the market is the increased investment in the establishment of biobanks. In July 2023, CU Medicine successfully established the CU-Med Biobank in Hong Kong, which is expected to turn into an important biomedical research hub in the region.
Based on the products and services, the market is segmented into equipment, consumables, services, and software.
By sample type, the market is divided into blood tissue, nucleic acids, and cell lines.
End users of the market are academic institutions, pharma, and biotech companies.
Major application areas include regenerative medicine, life science research, and clinical research.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are PHC Holdings Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Avantor, Inc., Cryoport, Inc., Tecan Trading AG, Lifecode Technologies Pte Ltd, and China Cord Blood Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER